Narcan-like drug delivery system approved for emergency treatment

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/DDurich)
(Image: Getty/DDurich)

Related tags: Fda, Drug delivery, Drug delivery systems, Technology, Diabetes

Aptar’s needle-free, emergency powder formulation treatment for patients with diabetes and severe hypoglycemia is the company’s first combination drug delivery device with active packaging.

AptarGroup’s intranasal drug delivery system was approved by the US Food and Drug Administration (FDA) for the needle-free rescue treatment of diabetic patients with severe hypoglycemia. The drug delivery solution is a single-use device that delivers a powder formulation to the nasal passages in an emergency.

Manufactured at Aptar’s site in Congers, New York, the Unidose System for powder is the company’s first combination drug delivery device with a protective active packaging container. It was developed by Aptar CSP Technologies and uses the company’s Activ-Polymer technology for moisture protection to ensure the shelf-life of the drug and mitigate any environmental conditions impacting the drug.

Stephan Tanda, Aptar’s president and CEO, said in a statement, “Our lab and analytic service capabilities combined with our unique drug delivery devices and active packaging solutions create tremendous value for our customers and help them secure approval. The ultimate end result is that we help expand access to life-saving treatments with our patient-friendly systems.”

The company offers single or two-shot intranasal delivery for a variety of medicines. However, the system has been used for liquid formulations and commercialized for numerous drug products, including Narcan, the nasal form of Naloxone, used for the treatment of opioid overdose.

According to a spokesperson for Aptar, intranasal drug delivery enables the drug to be quickly absorbed through the nasal mucosa making it an alternative to injectable kits.

The spokesperson said to produce a single-dose, the product must be primeless and, until recently, liquid formulations were the main drugs used in this type of delivery. However, a second wave of development saw a repurposing of the system to enable powder formulations.

Aptar Group also recently acquired two pharmaceutical services companies​, Nanopharma and Gateway analytical, to bolster its analytical, testing, and development capabilities. The company’s acquisition of Nanopharm saw Aptar gain access to its analytical and drug development services focused on orally inhaled and nasal drug products.

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more